



Patient: John A. Doe
DOB/Gender: 10/10/44 (74 yrs) - Male
Patient ID/MRN: 123456
Date Collected: 04/12/2019



Case#/Status: X19-00323 - Partial
Report Category:
Neoplastic



Provider: John Doe, M.D.
 Hematology Oncology Associates
 Tel: 800-123-4567
 Fax: 800-765-4321

PENDING STUDIES: Comprehensive assessment

Summary final report is expected on 04/18/19.
 Your patient's next appointment is on 04/25/19.

DIAGNOSIS: Bone marrow, aspirate: Monoclonal B-cell lymphocytosis (MBL) (see comment)

COMMENT

In the setting of an absolute lymphocyte count of $2.8 \times 10^9/L$, the presence of a CD5 positive, clonal population of B cells is consistent with a Monoclonal B-Cell Lymphocytosis (MBL). According to the 2016 WHO classification this falls into a "high count" MBL (between 0.5 and $5.0 \times 10^9/L$), for which routine annual follow-up is advised (Swerdlow SH et al., Blood 2016). In addition, less than 5% CD34 positive blasts are identified, supporting the blast count by aspirate smear.

INTERPRETATION






The differential shows increased granulocytes (88%). There is a total of 2% CD34 positive cells identified. The lymphocytes (2%) include 29% kappa-restricted B-cells, 60% mature T-cells with a normal CD4/CD8 ratio, and 13% natural killer (NK) cells. The CD138 positive plasma cells (<1%) have a polyclonal kappa/lambda phenotype. The B-cells show a loss of surface light chain expression and are partially positive for CD5, FMC7, and CD23, but negative for CD10 and CD103.

RESULT

Analysis Time: 4/12/19 13:04

Viability: 98% (Normal > 80%)

Specimen: BM, Lavender-top tube



Flow Cytometry Differential

Lymphocytes:	2%
Monocytes:	6%
Granulocytes:	88%
Plasma Cells:	<1%
Blasts:	1%
nRBC & Debris:	2%

Granulocytes


Lymphocytes & Plasma

Marker	%	Marker	%
CD4	8	CD2	73
CD10	28	CD4	27
CD11b	83	CD5	60
CD13	59	CD7	73
CD14	17	CD8	26
CD15	5	CD10	<1
CD16	48	CD11c	4
CD19	2	CD19	28
CD33	98	CD20	28
CD34	2	CD23	7
CD45	100	CD25	14
CD56	1	CD38	11
CD61	21	CD45	100
CD64	61	CD56	13
CD71	1	CD79b	17
CD117	9	CD103	1
HLA-DR	5	FMC-7	13
		Kappa	25
		Lambda	3
		sKappa	8
		sLambda	5
		ZAP-70	1


Electronically Signed By: Frank Bauer, MD (04/13/19 17:38)


Disclaimer: The adequacy of staining is verified by the appropriate positive and negative controls. The reagents used for these assays are analyte specific reagents (ASR). Their performance characteristics have been validated by Precipio, Inc., New Haven, CT. They have not been reviewed by the FDA. The FDA has deemed that such approval is unwarranted. These assays are for clinical use and should not be viewed as experimental or "research use only".

 **Patient:** John A. Doe

 **Case #:** X19-00323

 **Received:** 04/12/19 13:30

 **Reported:** 04/13/19 17:54

 **Received Information:** 2 Formalin containers, 9 smears, 1 touch prep, 2 green-top tubes, 1 lavender-top tube